Have an account? Log in.
I don't have an account.
FDA accepts Telix NDA for Pixclara for brain cancer imaging, analysts see confidence rebuild amid steady sales growth.
Telix Pharma stock climbs on strong Q1 growth and Phase 3 study success. Analysts maintain Buy ratings with price targets up to $22.00.
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.